Blueprint Medicines Corp is a United States-based patient-driven oncology company developing selective kinase inhibitors for genomically defined cancer subsets. The Company has developed a platform that combines genomics with a library of kinase inhibitors, to develop selective compounds against clear genomic driver targets. Its genomics expertise enables it to identify drug targets by sequencing unexplored cancers and mining public data with new genome analysis algorithms. KIT D816V is the validated driver mutation in Aggressive Systemic Mastocytosis (ASM); 95% of patients with ASM have this mutation. Its platform has developed a selective kinase drug to target this mutation.